Anemia

Ferric carboxymaltose vs. placebo in iron-deficient patients with acute HF.

FibroGen Inc. announced on Friday that the FDA is delaying a final review of the drug maker’s oral small molecule hypoxia-inducible factor prolyl hydroxylase inhibitor – roxadustat – for 3 months.

Treatment with imetelstat led to durable transfusion independence for certain heavily transfused patients with lower-risk myelodysplastic syndrome, according to study results published in Journal of Clinical Oncology.

Infectious endocarditis can present with rheumatic features in 15% to 25% of cases. This series focuses on what a rheumatologist should know about the clinical puzzle of endocarditis.

Supplementation in iron-deficient patients hospitalized with acute HF reduced subsequent HF hospitalization by approximately 26% compared with placebo, according to findings from the AFFIRM-AHF trial.

Vadadustat did not meet the primary safety endpoint of the PRO2TECT program for the treatment of anemia in patients with non-dialysis-dependent chronic kidney disease, according to data presented at ASN Kidney Week.

Jay B. Wish, MD, clinical medicine professor at Indiana University School of Medicine, reported that roxadustat was not linked to increased risk for neoplasm in patients with nondialysis- and dialysis-dependent chronic kidney disease.

In this video, Jay B. Wish, MD, professor of clinical medicine at Indiana University School of Medicine, discussed the insufficiency of current anemia treatment for non-dialysis-dependent patients with chronic kidney disease.

Patients with anemia and chronic kidney disease who receive roxadustat do not show an increased rate of neoplasm-related treatment-emergent adverse events and treatment-emergent serious adverse events, according to presented data.

Vadadustat demonstrated the efficacy and cardiovascular safety for the treatment of anemia in adult patients with dialysis-dependent chronic kidney disease, according to recently presented data.